Sunday Reading11 Dec 2022 10:13
The top 15 best-selling oncology drugs of 2022
https://www.fiercepharma.com/special-report/special-report-top-15-best-selling-cancer-drugs-2022
'If there was any doubt that the oncology market is set to reach unprecedented heights, FiercePharma's top 15 list of cancer drugs in 2022 should eliminate it.
All told, by 2022, the top 15 cancer drugs are expected to collectively make almost $90 billion in sales. To put that in perspective, that represents about one-fourth of the entire U.S. pharma market in 2014, according to QuintilesIMS data. It's also bigger than pharma's haul in Japan or China that year.
It will likely be no revelation that three drugs among the top six on our list—provided courtesy of EvaluatePharma and Chempetitive—come from the highly touted PD-1/PD-L1 or checkpoint inhibitor class.
This brand-new category of cancer drugs works by activating the immune system, enabling it to recognize cancer cells and destroy them. The class has achieved unprecedented efficacy in a broad range of cancers and provides a much-needed new treatment approach alongside chemotherapy and targeted cancer drugs, which tend to lose efficacy over time.'
Note so many MaBs!